

December 21, 2022

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001.

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark is the first company to launch in India a Triple FDC of Teneigliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Encl: as above

Press Release

For Immediate Release

**Glenmark is the first company to launch in India
a Triple FDC of Tenzeligliptin + Pioglitazone + Metformin
for Adults with Type 2 Diabetes & High Insulin Resistance**

- *This Fixed-Dose Combination (FDC) of Tenzeligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) SR under the brand name Zita®-PioMet.*
- *The novel triple FDC will help improve glycemic control among adults with High HbA1cⁱ and high insulin resistance, those whose diabetes is uncontrolled by metformin alone; and those who require the addition of Tenzeligliptin and Pioglitazone as separate drugs; thus improving adherence with single pill.*
- *Priced at Rs. 14.90 per day, it will reduce the daily cost of therapy by 40%, making it more affordable to the masses.*

Mumbai, India; December 21, 2022: Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company has launched the first triple fixed-dose combination Tenzeligliptin with Pioglitazone and Metformin in India. Tenzeligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor). This FDC has been launched under the brand name *Zita®-PioMet*, and contains Tenzeligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation. This offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks.

On occasion of the launch, Alok Malik, EVP & Business Head - India Formulations, Glenmark Pharmaceuticals Ltd., said, "Type 2 diabetes patients in India often face issues of beta cell dysfunction along with insulin resistance. In fact, the prevalence of high insulin resistance in India is 38% compared to the global incidence of 15%ⁱ. Being a leader in diabetes therapy in the country, we are proud to introduce Zita®-PioMet, India's first triple fixed dose combination for high insulin-resistant type 2 diabetes. The innovative, effective, and affordable drug will help improve the glycemic control among adult patients with high HbA1c."

Glenmark's Leadership in the Diabetes Segment

Glenmark has a strong legacy of bringing in new, effective and affordable treatment options for diabetic patients, especially the ones with uncontrolled Type 2 diabetes. In 2015, Glenmark was the first to launch the DPP4 inhibitor, Tenzeligliptin (*Zita Plus®* and *Ziten®*), followed by a FDC of Tenzeligliptin + Metformin (*Zita-Met Plus®* and *Ziten-M®*). Glenmark later launched Remogliflozin (*Remo®* and *Remozen™*), a novel SGLT-2 inhibitor in 2019 and subsequently, its combinations with Metformin and Vildagliptin (*Remo-V®*, *Remozen™-V*, *Remo MV®* and *Remozen™ MV*). Earlier in 2022, Glenmark also launched Sitagliptin (*Sitazit®*) and its FDCs, followed by Lobeglitazone (*LOBG®*) and FDCs of Tenzeligliptin including its combinations with Pioglitazone (*Zita Pio™*) and Dapagliflozin (*Zita-D™*).

Diabetes in India

According to IQVIA™ sales data for the 12-month period ending November 2022, the market for oral anti-diabetic drugs in India is estimated to be Rs. 11,877 Cr. with an annual growth of 6.3% against the corresponding period last year (MAT November 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045, 77% of which would have uncontrolled diabetes.

---End---

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world's top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world's top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world's most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com, LinkedIn (Glenmark Pharmaceuticals), Instagram (glenmark_pharma).

For more information, please contact

Udaykumar Murthy | +91 9960377617 | corpcomm@glenmarkpharma.com

References

i HbA1c is the average blood glucose (sugar) levels for the last two to three months.

ii Reference: Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables Lancet Diabetes Endocrinol 2018 6 :361–369